SecBot SecBot
PRESS-RELEASE ·Filed May 19, 2026

ARTV

Artiva Biotherapeutics, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Leadership
Actionable Insight • Neutral

This is a routine but positive leadership hire for a clinical-stage biotech. The stock may see a modest uptick on the credibility addition, but no catalyst triggers a re-rating. Watch for the initiation of the Phase 3 trial in refractory RA, if enrollment and early data are announced, that would be a material catalyst. Miralles' regulatory experience (PREZISTA, INTELENCE approvals) supports the BLA filing narrative, but execution risk remains high given no approved product and minimal cash disclosure.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.55
T+0 close · May 19, 2026 · via day close
Latest settled
+32.16%
T+60 · $11.30
Vs SPY
+25.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $8.55entry
  2. T+1 · 6mo ago −8.30%α −9.34% · $7.84
  3. T+5 · 6mo ago −8.19%α −10.43% · $7.85
  4. T+20 · 5mo ago +16.26%α +15.27% · $9.94
  5. T+60 · 3mo ago +32.16%α +25.87% · $11.30
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Artiva Biotherapeutics appointed Diego Miralles, M.D., as President and Head of R&D. Dr. Miralles brings >20 years of drug development experience including FDA approvals (PREZISTA, INTELENCE) and leadership at J&J Innovation, Vividion, and Laronde. He has served on Artiva's board since May 2024. The appointment is accompanied by an inducement grant of 232,500 options + 77,500 RSUs. The company is advancing AlloNK in autoimmune diseases and preparing for a Phase 3 registrational trial in refractory RA, with FDA alignment on a registrational path and a planned BLA submission in 2029. This is a clinical-stage biotech ($228M market cap) with no approved products and minimal revenue, the hire adds credibility but does not change the fundamental risk profile.

Key Facts

  • Diego Miralles, M.D., appointed President and Head of R&D, effective May 18, 2026
  • Miralles has >20 years leadership experience across research, clinical development, commercialization, and company building
  • He was CEO of Laronde and Vividion, and Global Head of Johnson & Johnson Innovation
  • Miralles has served on Artiva's Board of Directors since May 2024
  • Inducement grant: options for 232,500 shares + 77,500 RSUs, vesting over 4 years
  • Company advancing AlloNK toward Phase 3 registrational trial in refractory RA in 2026, BLA submission planned for 2029
  • Artiva is a clinical-stage biotech with no approved products or disclosed revenue; market cap ~$228M

Financial Impact

No immediate financial impact. Inducement grant of 310,000 total equity instruments (232,500 options + 77,500 RSUs) represents ~0.5% dilution on 52.4M shares outstanding (est.), offset by any potential long-term value from successful clinical development.

share count (dilution from equity grant)

Risk Factors

  • AlloNK is still early-stage; Phase 3 RA trial carries inherent clinical and regulatory risks
  • No disclosed cash runway, may need dilutive financing to fund Phase 3
  • Market cap of ~$228M leaves limited room for setback without significant stock decline

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3297380

Track record

33 reports on ARTV

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 8h 28m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026